Almirall, S.A.

BME:ALM 주식 보고서

시가총액: €1.8b

Almirall 과거 수익 실적

과거 기준 확인 0/6

Almirall의 수입은 연평균 -62.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 13.1%의 비율로 증가했습니다. 매출은 연평균 1%의 비율로 증가해 왔습니다.

주요 정보

-62.1%

수익 성장률

-61.0%

EPS 성장률

Pharmaceuticals 산업 성장5.0%
매출 성장률1.0%
자기자본 수익률-2.4%
순이익-3.8%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Is Almirall (BME:ALM) A Risky Investment?

May 16
Is Almirall (BME:ALM) A Risky Investment?

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29
Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01
Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06
Is Almirall (BME:ALM) Using Too Much Debt?

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05
How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15
Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

수익 및 비용 분석

Almirall 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

BME:ALM 수익, 비용 및 수입 (EUR Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24932-352200
31 Mar 24915-392143
31 Dec 23899-382090
30 Sep 2390772097
30 Jun 23898-112010
31 Mar 23882-82053
31 Dec 2287942020
30 Sep 22864920724
30 Jun 22856291970
31 Mar 22843-501908
31 Dec 21837-411880
30 Sep 21814-22201-10
30 Jun 21809-111850
31 Mar 2179055188-8
31 Dec 20814741770
30 Sep 2084963167-8
30 Jun 20872861880
31 Mar 209261211880
31 Dec 199111061890
30 Sep 19858852279
30 Jun 19884881820
31 Mar 19789802093
31 Dec 18811781830
30 Sep 18714-111176-10
30 Jun 18730-1791960
31 Mar 18687-293195-6
31 Dec 17677-3042070
30 Sep 17735-1282155
30 Jun 17755-782140
31 Mar 17821732165
31 Dec 16822752130
30 Sep 1677816223010
30 Jun 167431542100
31 Mar 167211112042
31 Dec 157381322010
30 Sep 15783479190-28
30 Jun 158024882440
31 Mar 15842481250-11
31 Dec 148284482740
30 Sep 14868-13262-11
30 Jun 14849-322560
31 Mar 14845-332610
31 Dec 13825-342500

양질의 수익: ALM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALM 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ALM 은(는) 수익성이 없으며 지난 5년 동안 연간 62.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ALM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALM 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 8.8% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: ALM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -2.36% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기